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Cancer Vaccines: A Ray of Hope
Abstract
In lieu of an abstract, here are the article's first two paragraphs:
Recent cancer statistics review by Surveillance, Epidemiology, and End Results (SEER) Program by
National Cancer Institute (NCI) shows that cancer is the second most leading cause of death after heart
diseases. Cancer incidence has grown from 19.2% to 23.3% from 1975 to 2010 (Figure 1)[1]. Lung cancer
remains to be the most fatal form of cancer followed by colorectal, breast and prostate cancer in the
country (Table 1)[1]. Regardless of several treatment options, cancer remains to be a unique challenge for
both patients and the healthcare providers. Several treatment options are available to address this
disease now. Chemotherapy, surgery, radiation therapy are still the mainline of treatment plan for cancer
patients. Along with these therapies, immunotherapy is being explored as a combination therapy.
Immunotherapy allows utilization of patient’s own immune system to combat the disease and⁄or assist in
avoiding a relapse.
Cancer research and clinical trials are one of the most challenging ones attributed to the nature of the
disease state. This editorial is devoted to those, who have dedicated their careers to develop various
immunotherapeutic approaches leading to the evolution of cancer vaccines, providing a ray of hope to
cancer patients. These cancer vaccines are targeted to boost the immune response of the host further
protecting them from the challenges posed by cancerous cells. Unlike vaccines for infectious diseases, a
cancer vaccine is targeted against host’s own cells. Thus, identification and isolation of such cancer
antigens is not only difficult but also unique for the patient at times.
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As we put forth the inaugural issue of Austin Journal of Cancer
and Clinical Research, I would like to take this opportunity to welcome
the readers and encourage fellow peers in academia, industry,
government and related healthcare professionals to contribute their
research work and expert reviews to the journal.
Recent cancer statistics review by Surveillance, Epidemiology,
and End Results (SEER) Program by National Cancer Institute (NCI)
shows that cancer is the second most leading cause of death after
heart diseases. Cancer incidence has grown from 19.2% to 23.3%
from 1975 to 2010 (Figure 1)[1]. Lung cancer remains to be the most
fatal form of cancer followed by colorectal, breast and prostate cancer
in the country (Table 1)[1]. Regardless of several treatment options,
cancer remains to be a unique challenge for both patients and the
healthcare providers. Several treatment options are available to
address this disease now. Chemotherapy, surgery, radiation therapy
are still the mainline of treatment plan for cancer patients. Along with
these therapies, immunotherapy is being explored as a combination
therapy. Immunotherapy allows utilization of patient’s own immune
system to combat the disease and/or assist in avoiding a relapse.
Cancer research and clinical trials are one of the most challenging
ones attributed to the nature of the disease state. This editorial is
devoted to those, who have dedicated their careers to develop various
immunotherapeutic approaches leading to the evolution of cancer
vaccines, providing a ray of hope to cancer patients. These cancer
vaccines are targeted to boost the immune response of the host further
protecting them from the challenges posed by cancerous cells. Unlike
vaccines for infectious diseases, a cancer vaccine is targeted against
host’s own cells. Thus, identification and isolation of such cancer
antigens is not only difficult but also unique for the patient at times.
Cancer vaccines are classified into two categories: prophylactic
and therapeutic. Prophylactic cancer vaccines are preventive vaccines,
currently there are two such vaccines available against cervical cancer.
Cervical cancer is caused by human papilloma virus (HPV) and
currently two FDA approved vaccines, Gardasil® and Cervarix®, are
available for its prevention. On the other hand, therapeutic vaccines
are administered post cancer diagnosis and are for treatment
purposes. Currently, Sipuleucel-T (Provenge® by Dendreon
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Corporation) is the only FDA approved therapeutic cancer vaccine.
Sipuleucel-T is a therapeutic cancer vaccine for metastatic prostate
cancer in males. Treatment with Sipuleucel-T is individualized; it
involves isolation of patient’s immune cells using leukapheresis and
then activation of their antigen presenting cells (APCs) ex vivo with
prostatic acid phosphatase and granulocyte-macrophage colonystimulating factor (PAP-GM-CSF). PAP is the prostate cancer
antigen, which is overexpressed in prostate cancer patients and
activation of APCs with PAP in presence of an immunostimulant
(GM-CSF) triggers an immune response. These activated APCs are
infused back into the patient leading to an immune response against
the cancerous cells expressing PAP antigen. These patients receive
three such treatments in an interval of two weeks each to obtain the
therapeutic effect. Sipuleucel-T based clinical trials have resulted in
an increase in survival rate of men suffering from metastatic prostate
cancer by an average of four months. Various limitations of being
eligible for the therapy, the cost and effort required to conduct the
procedure, reduced the number of patients being benefited by this
therapeutic vaccine.
Considering the potential of these cancer vaccines, various
ongoing clinical trials are utilizing different approaches to develop
cancer vaccines.Some of the antigen sources for these vaccines are:

•

Viral antigens

•

Whole cell lysates of cancer cells/weakened cancer cells

•

Protein/carbohydrate/glycolipid/ganglioside based cancer
antigens derived from cancer cells

•

DNA/RNA fragments responsible for tumor associated
antigens (TAAs)

Various immunostimulants/adjuvants have been employed to
enhance the immune response against these antigens, some examples
Table 1: Estimated number of new cancer cases and deaths in 2013 (SEER stat
fact sheet).
Common Types of Cancer

Estimated New
Cases 2013

Estimated
Deaths 2013

All Cancer Sites

1,660,290

580,350

1.

Lung and Bronchus Cancer

228,190

159,480

2.

Colon and Rectum Cancer

142,820

50,830

3.

Breast Cancer

232,340

39,620

4.

Prostate Cancer

238,590

29,720

5.

Non-Hodgkin Lymphoma

69,740

19,020

6.

Bladder Cancer

72,570

15,210

7.

Kidney and Renal Pelvis Cancer

65,150

13,680

8.

Melanoma of the Skin

76,690

9,480

9.

Endometrial Cancer

49,560

8,190

10.

Thyroid Cancer

60,220

1,850
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Figure 1: Leading causes of death in US. SEER cancer statistics review 1975-2010.

include: granulocyte-macrophage colony-stimulating factor (GMCSF), Bacillus Calmette-Guérin (BCG), cytosine phosphate-guanine
(CpG), interleukin-2/ interleukin-12, mono-phosphoryl lipid A
(MPL), etc[2].
With several promising cancer vaccine based clinical trials in the
pipeline, we continue to explore the potential of developing another
line of therapy for cancer patients. With this, I congratulate Austin
Journal of Cancer and Clinical Research for the inaugural issue and
encourage the readers to contribute to the scientific community
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through the journal.
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